Comparative Pharmacology
Head-to-head clinical analysis: ESLICARBAZEPINE ACETATE versus PARADIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESLICARBAZEPINE ACETATE versus PARADIONE.
ESLICARBAZEPINE ACETATE vs PARADIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes the inactive state of sodium channels, reducing high-frequency repetitive firing of neurons. It also modulates T-type calcium channels and enhances slow inactivation of sodium channels.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
400 mg orally once daily, titrated to a maintenance dose of 800-1200 mg once daily.
100 mg orally three times daily; maximum 600 mg/day.
None Documented
None Documented
Clinical Note
moderateEslicarbazepine acetate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateEslicarbazepine acetate + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateCyclophosphamide + Eslicarbazepine acetate
"The metabolism of Eslicarbazepine acetate can be decreased when combined with Cyclophosphamide."
Clinical Note
moderateTerminal half-life of eslicarbazepine is 13-20 hours (mean ~14 hours), supporting once-daily dosing.
12-24 hours (terminal); prolonged in renal impairment
Renal: ~90% (as glucuronide conjugates and unchanged drug; ~30% as eslicarbazepine acetate, ~60% as eslicarbazepine). Fecal: <1%. Biliary: negligible.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Category C
Category C
Anticonvulsant
Anticonvulsant
Phenytoin + Eslicarbazepine acetate
"The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenytoin."